InfuSystem Holdings, Inc (INFU): Nasdaq/NYSE listing notice — InfuSystem warned by NYSE American for failing to file 2023 10-K on time

InfuSystem Holdings, Inc

Received NYSE American non-compliance notice due to failure to file 2023 Annual Report by April 1, 2024.
Has up to six months initial cure period; may get additional six months at exchange's discretion.
Late filing stems from potential errors in expense classification (G&A vs. cost of sales) and ASC 842 lease accounting.
No assurance cure will be successful; failure could lead to suspension and delisting.
Company intends to regain compliance; stock ticker INFU on NYSE American.

item 3.01 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Listing & Compliance Notices SEC 8-K Item 3.01 confidence 0.95

InfuSystem Holdings, Inc received a nyse_american noncompliance notice notice regarding late filing (rules 1007).

Exchange: nyse american
Notice: noncompliance notice
Deficiency: late filing
Rules: 1007

Exact text from the filing

April 2, 2024 , InfuSystem Holdings, Inc. (the "Company") received notice from the NYSE Regulation (the "Notice") stating that the Company is not in compliance with the continued listing standards of the NYSE American LLC (the "Exchange") under the timely filing criteria included in Section 1007 of the NYSE American Company Guide (the "Company Guide") because the Company failed to timely file its Annual Report on Form 10-K for the year ended December 31, 2023 (the "Delinquent Report"), which was due to be filed with the Securities and Exchange Commission (the "SEC") no later than April 1, 2024

View on SEC.gov

20 listing & compliance notices filed in the last 30 days. Browse all listing & compliance notices →

InfuSystem Holdings, Inc filing history →

Source: SEC EDGAR

accession 0001628280-24-014470

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.